Short Interest in Altamira Therapeutics Ltd. (NASDAQ:CYTO) Rises By 12.8%

Altamira Therapeutics Ltd. (NASDAQ:CYTO) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 180,200 shares, an increase of 12.8% from the August 15th total of 159,800 shares. Approximately 8.1% of the shares of the company are short sold. Based on an average daily volume of 438,800 shares, the days-to-cover ratio is currently 0.4 days.

Altamira Therapeutics Stock Up 6.3 %

NASDAQ:CYTO opened at $0.79 on Wednesday. Altamira Therapeutics has a one year low of $0.73 and a one year high of $17.20. The firm’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.39.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.